Abstract
Icosapent ethyl (Vascepa®) is a high-purity ethyl ester of eicosapentaenoic acid (EPA), a long-chain omega-3 fatty acid associated with plasma triglyceride lowering. It does not contain the omega-3 fatty acid docosahexaenoic acid (DHA) that has been associated with increased low-density lipoprotein cholesterol (LDL-C) levels. Oral icosapent ethyl 2 g twice daily is approved in the USA for use as an adjunct to diet in lowering triglyceride levels in adult patients with severe hypertriglyceridaemia [triglyceride ≥500 mg/dL (≥5.65 mmol/L)]. In clinical trials in patients with very high or high triglyceride levels, icosapent ethyl 4 g/day significantly reduced triglyceride levels and other lipid parameters without increasing LDL-C levels, reduced levels of circulating markers of inflammation and was well tolerated. Case reports suggest that switching patients to icosapent ethyl from other omega-3 fatty acid products may improve lipid parameters.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
